Novartis presented over 65 abstracts at the 2026 ASCO and EHA meetings, highlighting new data on its radioligand therapy Pluvicto for prostate cancer, Kisqali for breast cancer, and Scemblix for chronic myeloid leukemia. The data reinforce Novartis' leadership in oncology with promising efficacy and safety results, including long-term outcomes and biomarker insights. Upcoming presentations will further detail novel therapies like ianalumab for immune thrombocytopenia and actinium-based radioligand therapy, underscoring Novartis' commitment to innovative cancer treatments.
The myasthenia gravis market, valued at around $6 billion in 2025, is projected to grow at a 9.1% CAGR to surpass $16 billion by 2036. Growth is fueled by increasing diagnosed cases, especially among older populations, and a surge in innovative targe...
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
